Top Story

Pfizer files suit claiming Johnson & Johnson stifles biosimilar competition

September 21, 2017

Pfizer, the manufacturer of Inflectra, a biosimilar to Janssen’s Remicade, filed a lawsuit against Johnson & Johnson, the parent company of Janssen, for “exclusionary contracts and other anticompetitive practices” that Pfizer maintains inhibits competition of their biosimilar in the approved markets.

“As evident by their success in markets such as Europe, we know biosimilars can improve patient access to important, life-saving medicines. We stand with patients and are fully committed to deliver on the increased therapeutic choices and potential savings that biosimilars can bring; however, we must make sure there are no artificial barriers in the commercial insurance market that may limit coverage and use of biosimilars,” John Young, Pfizer’s group president, essential health, said in a press release from Pfizer.

In the Journals

Methotrexate linked with adverse events in pediatric psoriasis

September 20, 2017
Methotrexate was associated with a higher rate of treatment-related adverse events than tumor necrosis factor inhibitors in a cohort of children with moderate to severe…
Meeting News

VOYAGE 1: Guselkumab yields encouraging outcomes in plaque psoriasis

September 19, 2017
At 100 weeks, more than 80% of patients with moderate to severe plaque psoriasis showed improvement after treatment with guselkumab, according to findings presented at…
Meeting News

Adalimumab biosimilar safety, efficacy matches Humira through 51 weeks

September 18, 2017
A biosimilar of adalimumab was associated with similar safety and efficacy outcomes compared with Humira in a cohort of patients with chronic plaque psoriasis, according…
More Headlines »